Luminex Corp (LMNX)

18.95
NASDAQ : Health Care
Prev Close 19.01
Day Low/High 18.87 / 19.18
52 Wk Low/High 17.64 / 23.62
Avg Volume 189.50K
Exchange NASDAQ
Shares Outstanding 44.07M
Market Cap 837.79M
EPS 0.30
P/E Ratio 76.04
Div & Yield 0.24 (1.30%)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAV, ARCC, BID, CFG, ENSG, EXEL, GCAP, HAE, HMLP, LGND, MOMO, MTW, PBR, RYI Downgrades: AEUA, ATSG, ATW, LMNX, MOH, MSB, NBEV, PAGP, SAVE, TIS Initiations: MCRB, TWLO Read on to get TheStreet Quant Ratings' detailed report:

Luminex Breaks Below 200-Day Moving Average - Notable for LMNX

In trading on Friday, shares of Luminex Corp crossed below their 200 day moving average of $19.90, changing hands as low as $19.80 per share. Luminex Corp shares are currently trading down about 1.4% on the day.

Luminex Corporation Receives FDA Clearance For ARIES C. Difficile Assay

Luminex Corporation Receives FDA Clearance For ARIES C. Difficile Assay

Sample to answer test provides detection of both toxin A and B

Luminex Corporation Receives CE-IVD Mark For ARIES® Norovirus Assay

Easy to use, sample to answer assay provides rapid detection of leading cause of acute gastroenteritis

YieldBoost Luminex Corp To 8.8% Using Options

Shareholders of Luminex Corp looking to boost their income beyond the stock's 1.2% annualized dividend yield can sell the January 2018 covered call at the $22.50 strike and collect the premium based on the 95 cents bid, which annualizes to an additional 7.7% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 8.8% annualized rate in the scenario where the stock is not called away. Any upside above $22.50 would be lost if the stock rises there and is called away, but LMNX shares would have to climb 9.2% from current levels for that to happen, meaning that in the scenario where the stock is called, the shareholder has earned a 13.8% return from this trading level, in addition to any dividends collected before the stock was called.

Luminex Corporation's VERIGENE Gram-Positive And Gram-Negative Blood Culture Panels Receive Reimbursement Approval In Japan

Molecular Assays Shorten Times to Results and Improve Management of Infectious Diseases

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKFS, CWAY, DE, EZPW, GSK, LMNX Downgrades: AMC, ESRT, MYOK, WERN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

LMNX Crosses Above Average Analyst Target

In recent trading, shares of Luminex Corp have crossed above the average analyst 12-month target price of $19.25, changing hands for $20.23/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Luminex Corporation Receives FDA Clearance For ARIES Bordetella Assay

Sample to answer assay provides accurate pertussis surveillance of clinically symptomatic patients

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

Here are Friday's top research calls, including upgrades for IberiaBank and Actuant, and downgrades for Kimberly-Clark and Ionis Pharma.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, HIHO, KE, LBRDA, SSP, TLRD, VIV Downgrades: CORE, LMNX, PKOH, SIM, TATT, TTEC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Toll Brothers and Luminex Initiate Dividends

In each case, the start of cash payouts follows better-than-expected quarterly results.

Relative Strength Alert For Luminex

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

LMNX: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/13/2017 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 11.24 "days to cover" versus the median component at 5.04. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

LMNX: Insiders vs. Shorts

LMNX: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/14/2016 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 16.32 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Oversold Conditions For Luminex (LMNX)

Oversold Conditions For Luminex (LMNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

LMNX Crosses Above Average Analyst Target

LMNX Crosses Above Average Analyst Target

In recent trading, shares of Luminex Corp have crossed above the average analyst 12-month target price of $21.67, changing hands for $21.95/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Luminex Stock Sees Short Interest Fall 10.7%

Luminex Stock Sees Short Interest Fall 10.7%

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 338,203 share decrease in total short interest for Luminex Corp , to 2,811,935, a decrease of 10.74% since 09/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

How to Cash in on the Fight Against the Zika Virus

How to Cash in on the Fight Against the Zika Virus

Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.

Commit To Purchase Luminex Corp At $20, Earn 15.8% Annualized Using Options

Commit To Purchase Luminex Corp At $20, Earn 15.8% Annualized Using Options

Investors considering a purchase of Luminex Corp shares, but cautious about paying the going market price of $20.04/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $20 strike, which has a bid at the time of this writing of $1.65.

Strong On High Volume: Luminex (LMNX)

Strong On High Volume: Luminex (LMNX)

Trade-Ideas LLC identified Luminex (LMNX) as a strong on high relative volume candidate

Insider Bets Paying Off At LMNX As New 52-Week High Reached

Insider Bets Paying Off At LMNX As New 52-Week High Reached

In trading on Tuesday, shares of Luminex Corp touched a new 52-week high of $21.94/share. That's a 45.78% rise, or $6.89 per share from the 52-week low of $15.05 set back on 02/03/2015.

Affymetrix And Luminex Announce Distribution Agreement For Multiplexed Assay Instrument Platform

Affymetrix And Luminex Announce Distribution Agreement For Multiplexed Assay Instrument Platform

Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ: LMNX) today announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex's MAGPIX ®,...

Luminex Enters Oversold Territory (LMNX)

Luminex Enters Oversold Territory (LMNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.